157 related articles for article (PubMed ID: 24016843)
21. Prostaglandin E2 stimulates osteoclast-like cell formation and bone-resorbing activity via osteoblasts: role of cAMP-dependent protein kinase.
Kaji H; Sugimoto T; Kanatani M; Fukase M; Kumegawa M; Chihara K
J Bone Miner Res; 1996 Jan; 11(1):62-71. PubMed ID: 8770698
[TBL] [Abstract][Full Text] [Related]
22. Alisol-B, a novel phyto-steroid, suppresses the RANKL-induced osteoclast formation and prevents bone loss in mice.
Lee JW; Kobayashi Y; Nakamichi Y; Udagawa N; Takahashi N; Im NK; Seo HJ; Jeon WB; Yonezawa T; Cha BY; Woo JT
Biochem Pharmacol; 2010 Aug; 80(3):352-61. PubMed ID: 20412788
[TBL] [Abstract][Full Text] [Related]
23. MS-275, a benzamide histone deacetylase inhibitor, prevents osteoclastogenesis by down-regulating c-Fos expression and suppresses bone loss in mice.
Kim HN; Lee JH; Jin WJ; Ko S; Jung K; Ha H; Lee ZH
Eur J Pharmacol; 2012 Sep; 691(1-3):69-76. PubMed ID: 22846626
[TBL] [Abstract][Full Text] [Related]
24. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
[TBL] [Abstract][Full Text] [Related]
25. Indapamide, a thiazide-like diuretic, decreases bone resorption in vitro.
Lalande A; Roux S; Denne MA; Stanley ER; Schiavi P; Guez D; De Vernejoul MC
J Bone Miner Res; 2001 Feb; 16(2):361-70. PubMed ID: 11204436
[TBL] [Abstract][Full Text] [Related]
26. Bone marrow cells produce soluble factors that inhibit osteoclast activity.
Ninomiya JT; Bi Y; Banks MA; Lavish SA; Goldberg VM; Greenfield EM
J Orthop Res; 1999 Jan; 17(1):51-8. PubMed ID: 10073647
[TBL] [Abstract][Full Text] [Related]
27. Differentiation of osteoblast and osteoclast precursors on pure and silicon-substituted synthesized hydroxyapatites.
Lehmann G; Cacciotti I; Palmero P; Montanaro L; Bianco A; Campagnolo L; Camaioni A
Biomed Mater; 2012 Oct; 7(5):055001. PubMed ID: 22781924
[TBL] [Abstract][Full Text] [Related]
28. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
[TBL] [Abstract][Full Text] [Related]
29. Macrophage colony stimulating factor increases bone resorption in dispersed osteoclast cultures by increasing osteoclast size.
Lees RL; Heersche JN
J Bone Miner Res; 1999 Jun; 14(6):937-45. PubMed ID: 10352102
[TBL] [Abstract][Full Text] [Related]
30. Tumor necrosis factor-alpha: alternative role as an inhibitor of osteoclast formation in vitro.
Balga R; Wetterwald A; Portenier J; Dolder S; Mueller C; Hofstetter W
Bone; 2006 Aug; 39(2):325-35. PubMed ID: 16580896
[TBL] [Abstract][Full Text] [Related]
31. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro.
Bonnelye E; Chabadel A; Saltel F; Jurdic P
Bone; 2008 Jan; 42(1):129-38. PubMed ID: 17945546
[TBL] [Abstract][Full Text] [Related]
32. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
Kneissel M; Luong-Nguyen NH; Baptist M; Cortesi R; Zumstein-Mecker S; Kossida S; O'Reilly T; Lane H; Susa M
Bone; 2004 Nov; 35(5):1144-56. PubMed ID: 15542040
[TBL] [Abstract][Full Text] [Related]
33. Stimulatory effect of insulin-like growth factor binding protein-5 on mouse osteoclast formation and osteoclastic bone-resorbing activity.
Kanatani M; Sugimoto T; Nishiyama K; Chihara K
J Bone Miner Res; 2000 May; 15(5):902-10. PubMed ID: 10804020
[TBL] [Abstract][Full Text] [Related]
34. Chloroform extract of deer antler inhibits osteoclast differentiation and bone resorption.
Li YJ; Kim TH; Kwak HB; Lee ZH; Lee SY; Jhon GJ
J Ethnopharmacol; 2007 Sep; 113(2):191-8. PubMed ID: 17646068
[TBL] [Abstract][Full Text] [Related]
35. Osteocytes subjected to fluid flow inhibit osteoclast formation and bone resorption.
Tan SD; de Vries TJ; Kuijpers-Jagtman AM; Semeins CM; Everts V; Klein-Nulend J
Bone; 2007 Nov; 41(5):745-51. PubMed ID: 17855178
[TBL] [Abstract][Full Text] [Related]
36. In vitro osteoclast formation and resorption of silicon-substituted hydroxyapatite ceramics.
Friederichs RJ; Brooks RA; Ueda M; Best SM
J Biomed Mater Res A; 2015 Oct; 103(10):3312-22. PubMed ID: 25847383
[TBL] [Abstract][Full Text] [Related]
37. Effects of geranylgeranoic acid in bone: induction of osteoblast differentiation and inhibition of osteoclast formation.
Wang X; Wu J; Shidoji Y; Muto Y; Ohishi N; Yagi K; Ikegami S; Shinki T; Udagawa N; Suda T; Ishimi Y
J Bone Miner Res; 2002 Jan; 17(1):91-100. PubMed ID: 11771673
[TBL] [Abstract][Full Text] [Related]
38. Inhibitory effects of Stewartia koreana on osteoclast differentiation and bone resorption.
Park CK; Kim HJ; Kwak HB; Lee TH; Bang MH; Kim CM; Lee Y; Chung DK; Baek NI; Kim J; Lee ZH; Kim HH
Int Immunopharmacol; 2007 Dec; 7(12):1507-16. PubMed ID: 17920527
[TBL] [Abstract][Full Text] [Related]
39. Platelets increase while serum reduces the differentiation and activity of osteoclasts in vitro.
Agis H; Schröckmair S; Skorianz C; Fischer MB; Watzek G; Gruber R
J Orthop Res; 2013 Oct; 31(10):1561-9. PubMed ID: 23703957
[TBL] [Abstract][Full Text] [Related]
40. Regucalcin stimulates osteoclast-like cell formation in mouse marrow cultures.
Yamaguchi M; Uchiyama S
J Cell Biochem; 2005 Mar; 94(4):794-803. PubMed ID: 15578574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
